RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Alnylam Pharmaceuticals Stock

Alnylam Pharmaceuticals Revenue 2024

Alnylam Pharmaceuticals Revenue

2.27 B USD

Ticker

ALNY

ISIN

US02043Q1076

WKN

A0CBCK

In 2024, Alnylam Pharmaceuticals's sales reached 2.27 B USD, a 24.38% difference from the 1.83 B USD sales recorded in the previous year.

The Alnylam Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e6.124,89
2028e4.8931,04
2027e3.8639,33
2026e3.5343,04
2025e2.6557,39
2024e2.2766,75
20231.8383,02
20221.0483,73
20210.8483,39
20200.4984,16
20190.2288,58
20180.0797,60
20170.091688,42
20160.053215,86
20150.043693,15
20140.052999,77
20130.053215,86
20120.072275,69
20110.081833,20
20100.11517,89
20090.11510,33
20080.11577,84
20070.052982,09
20060.035642,70
20050.0126629,58
2004035299,67

Alnylam Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Alnylam Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alnylam Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alnylam Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Alnylam Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Alnylam Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Alnylam Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alnylam Pharmaceuticals’s growth potential.

Alnylam Pharmaceuticals Revenue, EBIT and net profit per share

DateAlnylam Pharmaceuticals RevenueAlnylam Pharmaceuticals EBITAlnylam Pharmaceuticals Net Income
2029e6.1 B undefined0 undefined2.36 B undefined
2028e4.89 B undefined1.71 B undefined1.63 B undefined
2027e3.86 B undefined972.6 M undefined1.03 B undefined
2026e3.53 B undefined405.03 M undefined295.94 M undefined
2025e2.65 B undefined-114.22 M undefined-200.28 M undefined
2024e2.27 B undefined-370.52 M undefined-334.11 M undefined
20231.83 B undefined-282.18 M undefined-440.24 M undefined
20221.04 B undefined-785.1 M undefined-1.13 B undefined
2021844.3 M undefined-708.7 M undefined-852.8 M undefined
2020492.9 M undefined-828.4 M undefined-858.3 M undefined
2019219.8 M undefined-939.4 M undefined-886.1 M undefined
201874.9 M undefined-814.7 M undefined-761.5 M undefined
201789.9 M undefined-500.1 M undefined-490.9 M undefined
201647.2 M undefined-424.6 M undefined-410.1 M undefined
201541.1 M undefined-296 M undefined-290.1 M undefined
201450.6 M undefined-405 M undefined-360.4 M undefined
201347.2 M undefined-92.9 M undefined-89.2 M undefined
201266.7 M undefined-60.8 M undefined-106 M undefined
201182.8 M undefined-54.8 M undefined-57.6 M undefined
2010100 M undefined-41.9 M undefined-43.5 M undefined
2009100.5 M undefined-48.1 M undefined-47.6 M undefined
200896.2 M undefined-27.8 M undefined-26.2 M undefined
200750.9 M undefined-93.2 M undefined-85.5 M undefined
200626.9 M undefined-39.5 M undefined-34.6 M undefined
20055.7 M undefined-43.5 M undefined-42.9 M undefined
20044.3 M undefined-32.3 M undefined-35.4 M undefined

Alnylam Pharmaceuticals stock margins

The Alnylam Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alnylam Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alnylam Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Alnylam Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Alnylam Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Alnylam Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Alnylam Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alnylam Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alnylam Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alnylam Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Alnylam Pharmaceuticals Margin History

Alnylam Pharmaceuticals Gross marginAlnylam Pharmaceuticals Profit marginAlnylam Pharmaceuticals EBIT marginAlnylam Pharmaceuticals Profit margin
2029e83.02 %0 %38.63 %
2028e83.02 %34.87 %33.33 %
2027e83.02 %25.2 %26.75 %
2026e83.02 %11.48 %8.39 %
2025e83.02 %-4.32 %-7.57 %
2024e83.02 %-16.29 %-14.69 %
202383.02 %-15.43 %-24.08 %
202283.73 %-75.68 %-109.04 %
202183.39 %-83.94 %-101.01 %
202084.16 %-168.07 %-174.13 %
201988.58 %-427.39 %-403.14 %
201897.6 %-1,087.72 %-1,016.69 %
201783.02 %-556.28 %-546.05 %
201683.02 %-899.58 %-868.86 %
201583.02 %-720.19 %-705.84 %
201483.02 %-800.4 %-712.25 %
201383.02 %-196.82 %-188.98 %
201283.02 %-91.15 %-158.92 %
201183.02 %-66.18 %-69.57 %
201083.02 %-41.9 %-43.5 %
200983.02 %-47.86 %-47.36 %
200883.02 %-28.9 %-27.23 %
200783.02 %-183.1 %-167.98 %
200683.02 %-146.84 %-128.62 %
200583.02 %-763.16 %-752.63 %
200483.02 %-751.16 %-823.26 %

Alnylam Pharmaceuticals Aktienanalyse

What does Alnylam Pharmaceuticals do?

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA-based therapeutics for the treatment of severe genetic and other diseases. The company was founded in 2002 by John Maraganore and Phillip Sharp and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Alnylam Pharmaceuticals's Sales Figures

The sales figures of Alnylam Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Alnylam Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Alnylam Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Alnylam Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Alnylam Pharmaceuticals stock

How much revenue did Alnylam Pharmaceuticals generate this year?

Alnylam Pharmaceuticals has achieved a revenue of 2.27 B USD this year.

How much was the turnover of the company Alnylam Pharmaceuticals compared to the previous year?

The revenue of Alnylam Pharmaceuticals has increased by 24.38% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Alnylam Pharmaceuticals?

The revenue of Alnylam Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Alnylam Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Alnylam Pharmaceuticals so important for investors?

The revenue of Alnylam Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Alnylam Pharmaceuticals pay?

Over the past 12 months, Alnylam Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alnylam Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alnylam Pharmaceuticals?

The current dividend yield of Alnylam Pharmaceuticals is .

When does Alnylam Pharmaceuticals pay dividends?

Alnylam Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alnylam Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alnylam Pharmaceuticals located?

Alnylam Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alnylam Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alnylam Pharmaceuticals from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Alnylam Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Alnylam Pharmaceuticals in the year 2023?

In the year 2023, Alnylam Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alnylam Pharmaceuticals pay out the dividend?

The dividends of Alnylam Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Alnylam Pharmaceuticals

Our stock analysis for Alnylam Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alnylam Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.